Other
Blinatumomab
2
Pipeline Programs↗
14
Active Trials↗
2
Companies Involved↗
Blinatumomab is an early-stage landscape with 2 programs across 2 companies. The most active players are Amgen, Syndax Pharmaceuticals.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
2programs
Small molecule150%
Monoclonal antibody150%
Modality classified for 100% of 2 pipeline programs.
Analysis
Trial Status
21
clinical trials
Recruiting9 · 43%
Not yet recruiting5 · 24%
Unknown status3 · 14%
Completed2 · 10%
Terminated1 · 5%
Withdrawn1 · 5%
Clinical Trials
Trial Activity
21 trials
RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
Recruiting·—·Phase 2·NCT06250959·124 enrolled
Blinatumomab for CNI-Resistant/Intolerant SRNS in Children
Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 1·NCT06607991·6 enrolled
NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL
Not yet recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·N/A·NCT06763302·1,220 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)